Articles
Longer reads on peptide science and the evidence behind it. Factual statements cite their sources; none of it is advice. News
Questions answered
The questions people search for most about each compound, answered in one place, with the strength of the evidence shown beside every answer.
TB-500: Side Effects, Evidence, Legality and More, Answered18 questions
BPC-157 and TB-500 Together: Wolverine Stack Questions, Answered18 questions
BPC-157: Side Effects, Evidence, Legality and More, Answered19 questions
Retatrutide: Side Effects, Results, Legality and More, Answered19 questions
Articles
Reading a peptide label: FDA prescription labeling versus a research-use-only vial
What the sections of an FDA prescribing label tell you, using Wegovy and Zepbound as examples, and what a research-use-only label does not.
The thymosin family: thymosin alpha-1, thymosin beta-4 and TB-500
Thymosin alpha-1 and thymosin beta-4 share a name and an origin story but differ in structure, biology and evidence; TB-500 is a third thing.
Why so much peptide evidence comes from animals, and how to read it
BPC-157, TB-500 and epithalon are popular research peptides whose evidence is mostly cell and animal data. Here is how to weigh that.
How peptides are engineered to last longer in the body
Fatty-acid acylation, albumin binding, Fc fusion, PEGylation and D-amino acids: the main chemical strategies used to extend peptide half-life.
GLP-1, GIP and glucagon: from single to dual to triple agonists
What combining GLP-1, GIP and glucagon receptor activity has and has not shown in trials of semaglutide, tirzepatide, survodutide and retatrutide.
From Gila monster venom to weekly injections: a short history of GLP-1 drugs
How a gut hormone, a lizard venom peptide and decades of peptide chemistry led to once-weekly GLP-1 receptor agonists.
What FDA warning letters to peptide sellers say
A side-by-side reading of six FDA warning letters to online peptide sellers: intended-use evidence, research-use-only labels, code names and the charges FDA brings.
FDA's 2025-2026 review of peptides for compounding
What FDA's Category 2 changes, the July 2026 advisory committee votes and the 503A and 503B rules mean for compounded peptides, and what has not changed.
The incretin pipeline in 2026: dual and triple agonists, amylin combinations and oral agents
A status map of GLP-1, GIP, glucagon and amylin-based molecules as of 22 October 2026: which are approved, which are still in trials, and what the evidence does and does not show.
FDA in 2026: telehealth GLP-1 letters and a line on retatrutide
FDA sent 30 warning letters to telehealth firms over compounded GLP-1 marketing in March 2026, and its GLP-1 guidance page now states that retatrutide and cagrilintide cannot be used in compounding.
CagriSema in 2026: head-to-head results and a pending FDA decision
Novo Nordisk's cagrilintide/semaglutide combination missed non-inferiority to tirzepatide in REDEFINE 4, then reported superiority over a lower tirzepatide dose in REIMAGINE 5. An FDA decision is expected in Q4 2026.
Lilly files six lawsuits against US retatrutide sellers
On 12 August 2026 Eli Lilly announced six federal lawsuits against US businesses it says sell unapproved retatrutide, including sellers labelling the product "research use only". Retatrutide is not approved anywhere.
Retatrutide: Lilly reports TRIUMPH-2 and TRIUMPH-3 phase 3 results
On 23 July 2026 Lilly reported topline results from two more 80-week phase 3 trials of retatrutide and said it plans to submit the drug to FDA in the first quarter of 2027.